Pfizer Yields 6.25%. These 3 Dividend Stocks Pay More Than a 1-Year Treasury Bill
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The one-year Treasury bill yielded 4.59% as of November 18, 2026. That is a solid risk-free rate, and three dividend stocks from three different industries still pay more. Pfizer (NYSE:PFE | PFE Price Prediction), British American Tobacco (NYSE:BTI), and Enbridge (NYSE:ENB) carry forward yields of 6.25%, 5.81%, and 5.91% at current prices. Healthcare, tobacco, and pipelines give you three separate sources of cash flow, and each company has a stated plan for funding its payout.
Why a Dividend Carries More Risk Than a T-Bill
A T-bill locks in its yield the day you buy it, and the U.S. government backs repayment at maturity. A dividend stock carries two risks: the board can raise or cut the payout, and the share price can fall below what you paid. You get paid more for taking those risks, so each pick below starts with dividend safety: coverage, cash flow, debt, and a payment history checked against the actual record (we laid out the seven warning signs that a big yield is about to be cut in a free dividend trap guide).
Pfizer: Ultra-High-Yield Income Backed by a Raised Outlook
Yield: Pfizer pays $0.43 per quarter, or $1.72 a year. With the stock at $27.52, that works out to a 6.25% forward yield, which makes it the only ultra-high-yield name on this list. The next payment lands on December 7, 2026.
Dividend safety: Pfizer’s quarterly dividend records go back to 1999. The payout rose every year from $0.34 in 2018 to $0.43 in 2025, then stayed flat at that level for every 2026 payment. Earnings cover the dividend comfortably. Management raised 2026 adjusted EPS guidance to $2.95 to $3.05[1], compared with the $1.72 annual payout. Cash coverage is tighter. Operating cash flow through the third quarter was $8.8 billion[2], and dividends over the same nine months cost $7.3 billion. Leverage was 2.6 times[2] at quarter-end against a 2.7 times target for the year, with interest coverage at 6.52x. Pfizer has also set aside buybacks, with guidance assuming no share repurchases in 2026[1], so that cash can go to the dividend. Chief Financial Officer Cecile Guegan said directly that “through the LOE period, our operating cash flow, financial assets, and access to capital markets will give us the ability to continue to invest and maintain the dividend.”[2]
Bull case: The newer drugs are taking over from the COVID products. Third-quarter adjusted EPS came in at $0.87[1], beating the $0.728 consensus. Revenue of $16.583 billion[1] also exceeded the $15.877 billion estimate. Launched and acquired products grew 32% operationally[2]. Eliquis rose 25%[1] to $2.523 billion, and Padcev jumped 55%. The stock trades at about 10 times forward earnings. Despite a 17.96% gain this year, shares are down 7.26% over the past month.
Risk: Patent expirations, known in the industry as loss of exclusivity (LOE), are coming. Ibrance and Xtandi lose U.S. exclusivity, and Eliquis loses it internationally at the end of 2026[2]. Management expects leverage to stay “around current levels, or modestly higher”[2] through that period. U.S. drug-pricing rules (Most-Favored-Nation pricing and the Inflation Reduction Act) add more pressure. Pfizer plans to issue 2027 guidance in mid-December[2]. Investors should watch it, because it will be the first full read on how the company handles the patent losses.
British American Tobacco: Smokeless Growth Funding a Sterling Raise
Yield: British American Tobacco’s U.S. shares (ADRs) pay $0.834851 per quarter, or an annualized $3.339404. At $57.47 a share, the forward yield is 5.81%. The next ex-dividend date is December 29, 2026, with payment on February 8, 2027.
Dividend safety: BAT declared a 2025 dividend of 245.04p[3] per share, up 2.0%, paid in four installments of 61.26p. The company has committed to growing the dividend in sterling. U.S. holders receive dollars, so their payout moves with the exchange rate. The quarterly ADR amount went from $0.743059 in 2024 to $0.749068 in 2025 and $0.834851 in 2026. Cash support is strong. Operating cash flow was $6.342 billion[3] in 2025, and an older annual-filing target, worth checking, called for converting more than 95% of operating profit into cash. The target for leverage (adjusted net debt to adjusted EBITDA) is 2.0 to 2.5x by year-end, and the company has authorized a £1.3 billion[3] buyback for 2026.
Bull case: Nicotine pouches (modern oral) are growing fast enough to offset the decline in cigarettes. Modern Oral revenue rose 47.4%[3] to $1.165 billion, and Velo Plus revenue in the U.S. climbed 310%, making it the No. 2 U.S. modern oral brand. BAT added 4.7 million smokeless consumers for a total of 34.1 million. The stock trades at about 12 times forward earnings, and its beta of 0.086 means it has moved very little with the broader market. Analysts lean bullish: 1 strong buy, 5 buys, and 1 hold.
Risk: Cigarettes still bring in most of the money, with combustibles revenue of $20.201 billion[3], down 2.3%. Global cigarette volumes are expected to fall about 2% in 2026. Vapor revenue dropped 10.4%[3] as illegal disposable vapes took share. Dutch tax authorities have issued assessments that could total £1,082M, and 2026 guidance is at the low end of the company’s growth targets. The shares slipped 5.85% in the past week.
Enbridge: A Pipeline Toll Road With a Three-Decade Raise Record
Yield: Enbridge’s annualized forward dividend of $2.72 in U.S. dollars gives a 5.91% yield at $45.99 a share. The company declares its dividend in Canadian dollars, most recently C$0.97[4] per quarter, so the U.S. payout moves with the exchange rate. It was $0.712 in February 2026 and $0.68 for the payment due December 1, 2026.
Dividend safety: The 2026 guidance for distributable cash flow (DCF), the cash available to pay dividends, is C$5.70 to C$6.10[4] per share, which covers the quarterly C$0.97 payout. Management expects to land at the midpoint and says Enbridge is on track to meet its guidance for the 21st consecutive year. Incoming chief executive Michele Harradence pointed to “31 consecutive years of dividend increases,”[5] and the company’s dividend records go back to 1999. Enbridge returned $39 billion[5] in dividends over the past five years and expects to pay $40 billion to $45 billion over the next five.
Bull case: Pipelines charge fees for moving oil and gas, and that kind of business holds up well when the economy slows. Enbridge has a $38 billion[5] backlog of secured growth projects and expects about 5% annual growth through the end of the decade. Its Mainline crude system runs “at or near capacity,”[5] and Blackcomb came online with up to 2.5 Bcf/d of gas capacity. Enbridge also has 1.4 GW[5] of generation under construction backed by long-term contracts with Meta Platforms (NASDAQ:META). Chief executive Greg Ebel described it this way: “Our all-of-the-above approach to energy investment allows us to win in multiple ways, regardless of the commodity type, color of the electron, or, frankly, the ever-changing makeup of governments.”[5]
Risk: Debt and near-term earnings are the weak spots. Debt was 5.1 times[5] EBITDA at the end of the third quarter, above the company’s target range, and higher financing costs on new debt are cutting into cash flow growth. Third-quarter adjusted EPS of $0.3489 missed the $0.4936 consensus by 29.32%. The US$2.55B Tallgrass deal still needs regulatory approval, and the CEO changes hands on January 1[5].
How These Three Payers Stack Up Against T-Bills
Pfizer, British American Tobacco and Enbridge all yield more than the 4.59% T-bill, and each backs its payout with cash flow, a defined debt target and a long payment record. Their profile matches a multi-year horizon that can absorb price drops in exchange for income with room to grow, plus diversification across healthcare, tobacco, and energy infrastructure. For anyone who needs every dollar of principal back on a fixed date, or who can’t stomach a dividend freeze or a price drop, T-bills provide the certainty these stocks lack.
Contact [email protected] for any questions or corrections.







